The latest price target for Assembly Biosciences (NASDAQ:ASMB) was reported by Mizuho on November 20, 2025. The analyst firm set a price target for $40.00 expecting ASMB to rise to within 12 months (a possible 17.86% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Assembly Biosciences (NASDAQ:ASMB) was provided by Mizuho, and Assembly Biosciences maintained their outperform rating.

The last upgrade for Assembly Biosciences Inc happened on September 20, 2024 when Jefferies raised their price target to $35. Jefferies previously had a hold for Assembly Biosciences Inc.

There is no last downgrade for Assembly Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Assembly Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Assembly Biosciences was filed on November 20, 2025 so you should expect the next rating to be made available sometime around November 20, 2026.

While ratings are subjective and will change, the latest Assembly Biosciences (ASMB) rating was a maintained with a price target of $29.00 to $40.00. The current price Assembly Biosciences (ASMB) is trading at is $33.94, which is within the analyst’s predicted range.